Invenra has invented and developed a new screening platform PureProPep (P3) that enables unprecedented discovery opportunities in this space. The P3 Technology enables scientists to create and screen large, high-value, libraries against the cell-based phenotype assays preferred by pharmaceutical companies.
Invenra Announces Expansion of Collaboration with Exelixis
MADISON, WI, USA, Oct 31, 2019 – Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc. (Nasdaq: EXEL). Exelixis and Invenra had entered into a collaboration on May 2nd, 2018 to discover and develop multispecific antibodies through the use...
Invenra and WARF Initiate a Collaboration to Discover and Develop Novel Therapeutics to Fight Neuroblastoma in Children
Madison, WI. Jan 31, 2019 – Invenra and WARF (Wisconsin Alumni Research Foundation) today announced they have entered into a collaboration to discover and develop a bispecific antibody therapeutic for the treatment of neuroblastoma, a cancer that is the third most...
From poet and ski bum to disease fighter: Roland Green
JUDY NEWMAN jdnewman@madison.com Dec 2, 2018 CEO Roland Green, left, talks with scientist Daniel Gerhardt at Invenra's labs, 505 S. Rosa Road, where researchers are developing cancer-fighting drugs. Green majored in English literature then switched to environmental...
Invenra Secures $7M in Series B Growth Round to Accelerate Bispecific Antibody Development
MADISON, Wis. – October 17, 2018 – Invenra, an antibody drug discovery and development company with novel multispecific platforms and product candidates, announced the close of a $7M Series B financing round. The financing will be used to expand the company to meet...